Equities analysts expect Paratek Pharmaceuticals Inc (NASDAQ:PRTK) to post sales of $2.12 million for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Paratek Pharmaceuticals’ earnings. The highest sales estimate is $3.02 million and the lowest is $1.00 million. Paratek Pharmaceuticals reported sales of $40,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 5,200%. The company is expected to announce its next quarterly earnings results on Thursday, August 1st.
On average, analysts expect that Paratek Pharmaceuticals will report full-year sales of $18.45 million for the current financial year, with estimates ranging from $9.90 million to $57.71 million. For the next financial year, analysts anticipate that the firm will report sales of $53.08 million, with estimates ranging from $22.58 million to $131.17 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that follow Paratek Pharmaceuticals.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.19) by $0.09. The business had revenue of $1.60 million during the quarter, compared to analyst estimates of $0.89 million. Paratek Pharmaceuticals had a negative net margin of 642.70% and a negative return on equity of 232.61%.
Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc lifted its holdings in shares of Paratek Pharmaceuticals by 3.2% in the third quarter. Vanguard Group Inc now owns 1,392,044 shares of the specialty pharmaceutical company’s stock worth $13,504,000 after buying an additional 43,816 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Paratek Pharmaceuticals by 5.7% in the third quarter. Bank of New York Mellon Corp now owns 136,376 shares of the specialty pharmaceutical company’s stock worth $1,323,000 after buying an additional 7,332 shares in the last quarter. Quinn Opportunity Partners LLC lifted its holdings in shares of Paratek Pharmaceuticals by 28.6% in the fourth quarter. Quinn Opportunity Partners LLC now owns 86,722 shares of the specialty pharmaceutical company’s stock worth $445,000 after buying an additional 19,284 shares in the last quarter. Teton Advisors Inc. lifted its holdings in shares of Paratek Pharmaceuticals by 350.0% in the fourth quarter. Teton Advisors Inc. now owns 108,000 shares of the specialty pharmaceutical company’s stock worth $554,000 after buying an additional 84,000 shares in the last quarter. Finally, Rhumbline Advisers lifted its holdings in shares of Paratek Pharmaceuticals by 50.0% in the fourth quarter. Rhumbline Advisers now owns 41,198 shares of the specialty pharmaceutical company’s stock worth $211,000 after buying an additional 13,733 shares in the last quarter. 73.79% of the stock is currently owned by hedge funds and other institutional investors.
PRTK opened at $4.18 on Monday. The company has a market capitalization of $135.50 million, a price-to-earnings ratio of -1.17 and a beta of 1.52. Paratek Pharmaceuticals has a 1-year low of $4.02 and a 1-year high of $12.30. The company has a debt-to-equity ratio of 14.48, a current ratio of 14.06 and a quick ratio of 13.95.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Featured Article: Do back-end load funds outperform no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.